On the 7 June 2004 Prana released a 59-page prospectus relating to release of 7 million American Depositary Receipts (ADR's). Contained in it is a section entitled "Risk Factors", warning prospective purchasers of the risks associated with the ADR's. When I read it, it sounded rather ominous. Included in the rhetoric is stuff like this -- "there is a high risk that we will not be able to complete the development of PBT-1, PBT-2 or develop other pharmaceutical products"; “we have limited manufacturing experience, and delays in manufacturing sufficient quantities of PBT-1 or PBT-2 for pre-clinical trials may negatively impact our business and operations”; etc. Since I have only just recently bought PBT, I couldn't help but wonder what the effect of such statements will be on the Australian SP. Does anybody wish to comment?
On the 7 June 2004 Prana released a 59-page prospectus relating...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $3.54K | 1.169M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 82714032 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 281957 | 2 |
View Market Depth
| Last trade - 15.59pm 20/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |